Skip to content

Study · Randomized controlled trial · n = 20 · 2012

5 results

May etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study.

Migliore A, Massafra U, Bizzi E, Argento G, Diamanti AP, Germano V, Tormenta S, Arduini F, Iannessi F, Granatas M, Laganà B

European review for medical and pharmacological sciences1 Mar 2012Cited by 9 (Europe PMC)

PMID22530354 (opens in a new tab)PepBankPUB-22530354
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with rheumatoid arthritis, adding teriparatide did not change new MRI erosion occurrence compared with etanercept alone, with none in either arm.

    In plain wordsIn adults with rheumatoid arthritis, neither teriparatide added to etanercept nor etanercept alone resulted in new MRI erosions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableNew MRI erosions
    Study

    n = 20

    Comparator
    Etanercept alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    At 52 weeks, there were no new MRI erosions in two arms.
    2 context sentences
    Summary · context
    Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled.
    Summary · context
    Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with rheumatoid arthritis, bone oedema improved in both arms without a difference after teriparatide addition.

    In plain wordsIn adults with rheumatoid arthritis, adding teriparatide did not improve bone swelling scores more than etanercept alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone oedema score
    Study

    n = 20

    Comparator
    Etanercept alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mg · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone oedema scores were significantly improved at 52 weeks in favour of both treatments versus baseline scores, without inter-groups differences.
    2 context sentences
    Summary · context
    Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled.
    Summary · context
    Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg).

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In adults with rheumatoid arthritis, the teriparatide-plus-etanercept arm showed no erosion healing, and the trial missed its primary endpoint.

    In plain wordsIn adults with rheumatoid arthritis, no erosions healed in the teriparatide-plus-etanercept arm.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableErosion healing
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The study did not achieve its primary endpoint of healing erosions. In the active arm no healing of erosions was found.
    2 context sentences
    Summary · context
    Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled.
    Summary · context
    Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In adults with rheumatoid arthritis, X-ray patterns remained unchanged with teriparatide plus etanercept and with etanercept alone.

    In plain wordsIn adults with rheumatoid arthritis, X-rays remained unchanged with teriparatide plus etanercept and with etanercept alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableX-ray patterns
    Study

    n = 20

    Comparator
    Etanercept alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    X-ray patterns were unchanged in all patients of both groups. No new erosions or previous erosions' healing were observed.
    2 context sentences
    Summary · context
    Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled.
    Summary · context
    Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialSafety outcome

    In adults with rheumatoid arthritis, no adverse events were reported with teriparatide plus etanercept or etanercept alone.

    In plain wordsIn adults with rheumatoid arthritis, neither treatment arm reported adverse events.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAdverse events
    Study

    n = 20

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No AEs were reported.
    2 context sentences
    Summary · context
    Twenty adult patients with active RA diagnosed according to American Rheumatism Association (ARA) criteria at least 6 months before study begin were enrolled.
    Summary · context
    Eligible patients were randomized to receive a standard dosage of etanercept (50 mg/week) or etanercept at same dosage with an addition of teriparatide (20 mg).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.